Early intervention with tirzepatide or semaglutide influences anti-atherosclerotic effects in ApoE knockout mice.
Tirzepatide and semaglutide just went head-to-head in an atherosclerosis study. Researchers at Kawasaki Medical School put both peptides through the paces in ApoE knockout mice — a classic model for vascular research. The goal: see how early intervention with these incretin receptor agonists shifts the needle on arterial plaque and inflammation.
Sci Rep
by Dan K, Sanada J, Kimura T et al.
“Early intervention with tirzepatide or semaglutide influences anti-atherosclerotic effects in ApoE knockout mice. Dan K(1), Sanada J(1), Kimura T(2), Iwamoto Y(1), Sugisaki T(1), Iwamoto H(1), Fushimi Y(1), Nogami Y(1), Shirakiya Y(1), Shimoda M(1), Nakanishi S(1), Kaku K(1), Kaneto H(1). Author information: (1)Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, 577 Matsushima, Kurashiki, 701-0192, Japan. (2)Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, 577 Matsushima, Kurashiki, 701-0192, Japan. tomohiko@med.kawasaki-m.ac.jp. This study aimed to investigate the anti-atherosclerotic properties of tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist, in comparison with semaglutide, a selective GLP-1 receptor agonist. ApoE knockout mice were divided into early diabetes (dosed from 10 to 22 weeks of age), late diabetes (dosed from 18 to 30 weeks of age), and non-diabetic groups after streptozotocin treatment, and each group received semaglutide, tirzepatide, or saline for 12 weeks. In the early diabetes group, both agents significantly suppressed aortic plaque formation compared with control, while modestly improving glycemia and lipid levels. No significant vascular effects were observed in late diabetes or non-diabetic groups. Tirzepatide markedly reduced inflammatory mediators, including Mcp-1, Il-6, I-cam, and Cd68, whereas semaglutide showed partial overlap. Notably, these anti-inflammatory effects were also detected in non-diabetic mice, suggesting vascular protection may involve arterial actions independently of metabolic control. Taken together, our findings demonstrate that tirzepatide exerts anti-atherosclerotic effects comparable to semaglutide, supporting the concept that GIP and GLP-1 signaling can confer vascular benefits. These results highlight the potential clinical relevance of dual incretin receptor agonism for cardiovascular risk reduction, although further studies are required to clarify the specific role of GIP signaling. © 2026. The Author(s). Conflict of interest statement: Declarations. Competing interests: T.K. has received honoraria for lectures from Novo Nordisk Pharma and Sumitomo Pharma. S. N. has received honoraria for lectures from Novo Nordisk Pharma and Daiichi Sankyo. K.K. has served as an advisor to, received honoraria for lectures from and received scholarship grants from Novo Nordisk Pharma, Sanwa Kagaku, Taisho Pharma, Kowa, Sumitomo Pharma, Mitsubishi Tanabe Pharma, Astellas and Boehringer Ingelheim. H.K. has received honoraria for lectures, scholarship grants and research grants from Novo Nordisk Pharma, Sanofi, Eli Lilly, Boehringer Ingelheim, Taisho Pharma, Sumitomo Pharma, Takeda Pharma, Ono Pharma, Daiichi Sankyo, Mitsubishi Tanabe Pharma, Kissei Pharma, MSD, AstraZeneca, Astellas, Novartis, Kowa and Abbott. All other authors have no conflict of interest.”
The setup was simple. Mice were split into early diabetes, late diabetes, and non-diabetic groups. Each got tirzepatide, semaglutide, or saline for 12 weeks. The most striking results showed up in the early diabetes group.
Both tirzepatide and semaglutide significantly suppressed aortic plaque buildup compared to controls
Modest improvements in blood sugar and lipid levels were seen, but the vascular effects stood out
No real vascular changes were seen in late diabetes or non-diabetic mice, except for inflammation markers
Tirzepatide did more than just reduce plaque. It delivered a strong anti-inflammatory punch, sharply lowering Mcp-1, Il-6, I-cam, and Cd68 expression. Semaglutide had some overlap but didn’t go as far. Interestingly, these anti-inflammatory effects weren’t limited to diabetic mice. Even non-diabetic animals showed reduced arterial inflammation, hinting at direct vascular benefits beyond metabolic shifts.
Key takeaway: Early use of tirzepatide or semaglutide can blunt atherosclerosis in this model, with tirzepatide showing extra anti-inflammatory action. The findings add momentum to the idea that dual GIP/GLP-1 agonists might have unique cardiovascular research potential.
Looking for a source? Check the vendor directory for peptides from trusted suppliers. This study makes a strong case for digging deeper into how these compounds shape vascular health.
Related Reading
Reply: Semaglutide in Frail HFpEF: Need for Objective Functional Measures and Body Composition Assessment.
News · JACC Heart FailSemaglutide in Frail HFpEF: Need for Objective Functional Measures and Body Composition Assessment.
News · NeuropsychopharmacologyIdentification of an intrusive-hypervigilant phenotype of posttraumatic stress symptoms with unique stress peptide and amygdala functional connectivity profiles.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.